Cited by 419Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCancer-related cognitive impairment studies

β-Amyloid burden in healthy aging: Regional distribution and cognitive consequences

Open access
Rodrigue, K.M., Kennedy, K.M., Devous, M.D., Rieck, J.R., Hebrank, A.C., Diaz-Arrastia, R., Mathews, D., Park, D.C.·2012·Neurology

Abstract

OBJECTIVE: Several lines of evidence suggest that pathologic changes underlying Alzheimer disease (AD) begin years prior to the clinical expression of the disease, underscoring the need for studies of cognitively healthy adults to capture these early changes. The overall goal of the current study was to map the cortical distribution of β-amyloid (Aβ) in a healthy adult lifespan sample (aged 30-89), and to assess the relationship between elevated amyloid and cognitive performance across multiple domains. METHODS: A total of 137 well-screened and cognitively normal adults underwent Aβ PET imaging with radiotracer (18)F-florbetapir. Aβ load was estimated from 8 cortical regions. Participants were genotyped for APOE and tested for processing speed, working memory, fluid reasoning, episodic memory, and verbal ability. RESULTS: Aβ deposition is distributed differentially across the cortex and progresses at varying rates with age across cortical brain regions. A subset of cognitively normal adults aged 60 and over show markedly elevated deposition, and also had a higher rate of APOE ε4 (38%) than nonelevated adults (19%). Aβ burden was linked to poorer cognitive performance on measures of processing speed, working memory, and reasoning. CONCLUSIONS: Even in a highly selected lifespan sample of adults, Aβ deposition is apparent in some adults and is influenced by APOE status. Greater amyloid burden was related to deleterious effects on cognition, suggesting that subtle cognitive changes accrue as amyloid progresses.

Integrity signals

Registry

Crossref · 10.1212/wnl.0b013e318245d295

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Rodrigue, K. M., Kennedy, K. M., Devous, M. D., Rieck, J. R., Hebrank, A. C., Diaz-Arrastia, R., Mathews, D., & Park, D. C.
Affiliations
The University of Texas at Dallas (US)
Venue
Neurology
Published
2012-02-07
Volume
78
Issue
6
Pages
387-395
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2037403969
Cited by
419
References
6
Citations by year
2026: 14 · 2025: 22 · 2024: 25 · 2023: 22 · 2022: 43 · 2021: 31 · 2020: 30 · 2019: 29 · 2018: 28 · 2017: 32 · 2016: 24 · 2015: 32 · 2014: 28 · 2013: 40 · 2012: 19
FWCI
27.18
Type
journal article
Language
en
Open access
Locations
  • Neurology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Alzheimer's Association (IIRG-09-135087)
  • National Institutes of Health (AG12300, AG-036848)
  • Avid Radiopharmaceuticals (5R37AG-006265)
  • National Institute on Aging (3R37AG-006265-25S1, P30AG012300, P30AG-12300, R00AG036848, AG-036848, R00AG036818, 1K99-AG-036848-1, K99AG036848, R37AG006265, AG 12300)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
Keywords
amyloid-beta, amyloid PET, 18F-florbetapir, healthy aging, Alzheimer's disease, APOE ε4, cognitive performance, processing speed, working memory, fluid reasoning, episodic memory, verbal ability, preclinical Alzheimer's disease
MeSH terms
Adult, Aged, Aged, 80 and over, Aging, Alzheimer Disease, Brain, Cognition, Cognition Disorders, Female, Humans, Male, Memory, Middle Aged, Neuropsychological Tests, Radionuclide Imaging, Amyloid beta-Peptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review